At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 599 enrolled
Drug / intervention
Influenza vaccine GSK2321138A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine GSK2321138A in Healthy Children
In Brief
A Phase 2 clinical trial evaluating Influenza vaccine GSK2321138A and Fluarix™ for Influenza. Completed, enrolled 599 participants across 2 sites.
Detailed Summary
The purpose of the present study is to assess the immunogenicity and safety of vaccine GSK2321138A in children.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesMexico
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartOct 2009
Primary CompletionMay 2010
TodayJul 2026
First PostedSep 28, 2009
Enrollment StartOct 8, 2009
Primary CompletionMay 21, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.8 years ago
Interventions
Influenza vaccine GSK2321138Abiological
Intramuscular injection
Fluarix™biological
Intramuscular injection